| 1 | Proteome-wide Mendelian Randomization Analysis Identified Potential Drug |
|------------------|---|
| 2 | Targets for Myocardial Infarction |
| 3 | |
| 4 | Xufeng Ye ¹ , Xinpei Wang ¹ , Jinzhu Jia ^{1,2*†} |
| 5 | 1Department of Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, |
| 6 | Haidian District, 100191, China. |
| 7 | 2Center for Statistical Science, Peking University, 100871, China. |
| 8 | |
| 9 | *Corresponding author(s). E-mail(s): jzjia@math.pku.edu.cn; |
| 10 | Contributing authors: yexufeng2017@pku.edu.cn; w-xp@pku.edu.cn; |
| 11 | †These authors contributed equally to this work. |
| 12 | |
| 13 | Subtitle: Potential Drug Targets for Myocardial Infarction |
| 14 | Word count: |
| 15 | #Correspondence and requests for reprint: |
| 16 | Dr. Jinzhu Jia, PhD, Department of Biostatistics, School of Public Health, Peking University, |
| 17 | China. 38 Xueyuan 14 Road, Bejing, 100191 China. Phone: (86) 010-82801528. Email: |
| 18 | jzjia@pku.edu.cn |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| ১ । ১১ | |
| ა∠ ეე | |
| 33 24 | |
| 34 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |

- 42
- 43

44 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

Abstract 2

3 Background: Myocardial infarction (MI) is a leading cause of global mortality. Finding effective 4 drugs to treat MI is an urgent concern for clinicians. Proteome- wide Mendelian randomization 5 (MR) analysis provides a new way to investigate invaluable therapeutic drug targets more 6 efficiently.

7

8 **Methods:** Using a proteome-wide MR approach, we assessed the genetic predictive causality 9 between thousands of plasma proteins and MI risk. First, by adopting several principles to judge 10 genetic variants associated with plasma proteins and MI risk, we selected a series of suitable 11 variants utilized as instrumental variables (IVs) for the latter Mendelian Randomization (MR) 12 analysis. Second, we performed a proteome-wide MR analysis to select candidate proteins. Third, 13 sensitivity tests including heterogeneity test, reverse causality test, and colocalization analyses 14 were conducted to ensure the robustness of our selected protein. Last, we assessed the drugability 15 of the identified potential drug targets for MI using databases including DrugBank, PharmGKB, 16 and TTD.

17

18 Results: Of the identified IVs, 3,156 associated with 1,487 plasma proteins were validated. 15 proteins exhibited significant genetically predicted causal associations (P - value $< 3.362 \times 10^{-5}$) 19 20 with MI risk, including Plasmin, MSP, Apo B, TAGLN2, LRP4, C1s, Angiostatin, Apo C-III, 21 PCSK9, ANGL4, FN1.4, Apo B, IL-6 sRa, SWAP70, FN, FN1.3. Sensitivity analyses pinpointed 22 Plasmin and Angiostatin for heterogeneity and proteins MSP, Apo B, and Angiostatin for reverse 23 causality effects. Colocalization analysis found several proteins sharing genetic variants with MI, 24 notably Apo B, TAGLN2, LRP4, C1s, Apo C-III, PCSK9 and ANGL4. When the threshold was 25 lowered to 0.7, additional variants SWAP70 could be contained. 7 potential drug targets for MI 26 were identified: SWP70, TAGLN2, LRP4, C1s, Apo C-III, PCSK9, and ANGL4. Drugability 27 assessment categorized these proteins into varying therapeutic potential categories, from 28 successfully drugged targets to those only reported in the literature.

29

30 Conclusion: Our comprehensive study elucidated 7 promising drug targets offering profound 31 insights into its molecular dynamics and presenting potential pathways for therapeutic 32 interventions against MI.

33

34 Keywords: Myocardial infarction, plasma protein, drug target, Mendelian randomization

- 35
- 36 37
- 38
- 39
- 40
- 41
- 42
- 43

| C | linical Perspective |
|-------------|---|
| 1) V | Vhat Is New? |
| ∗ Т in n | The analysis of thousands of proteins has identified 7 proteins that have a potential causal role ayocardial infarction risk. |
| ★ F have | Your of these ten proteins have drugs approved or in development that target them, and three 5 e not been previously reported to be associated with atrial fibrillation risk. |
| 2) V | What Are the Clinical Implications? |
| ∗ Т myc | The results of the present study demonstrate new potential drug/therapeutic targets for peardial infarction. |

Non-standard Abbreviations and Acronyms

| myocardial infarction |
|----------------------------------|
| Food and Drug Administration |
| genome-wide association study |
| instrumental variable |
| inverse variance weighted method |
| linkage disequilibrium |
| minor allele frequency |
| major histocompatibility complex |
| mendelian randomization |
| quantitative trait locus |
| single nucleotide polymorphism |
| therapeutic target database |
| |



1

2

Introduction 3

4 Myocardial Infarction (MI) ranks among the primary cardiovascular diseases world-wide, which 5 mainly originates from insufficient or interrupted blood supply via the coronary arteries, leading to 6 cardiac muscle damage or necrosis [1]. Despite advancements in risk factor management and 7 pharmaceutical interventions aiming to alleviate the burden of MI, its incidence and prevalence 8 have steadily surged in the past two decades and will be rising in the forthcoming decades [2]. 9 Contemporary therapeutic strategies, encompassing both extant and drugs under development, 10 often come under scrutiny due to concerns regarding their safety and efficiently [3]. Consequently, 11 the pursuit for more efficient and safe drug targets is at the forefront of clinicians and researchers' 12 priorities.

13

14 Proteomic Considerations in MI Pathophysiology

15 Proteins play a vital role in various biological processes at the cellular level, establishing 16 themselves as crucial components for potential drug targets [4-6]. Numerous studies have 17 underscored a significant correlation between levels of various plasma proteins and the risk of MI 18 [7–9]. However, the inherent constraints of observational research, such as residual confounding 19 and potential reverse causality, render these significant observations non-representative of clear 20 causal relationships [10, 11].

21

22 Advancements in Cardiovascular Risk Factor Targeting

23 Cardiovascular risk factor identification and targeted causal inference have made remarkable 24 strides in the prevention and treatment of coronary artery diseases, including MI. Propelled by 25 modern medical advancements, epidemiological studies have investigated hundreds of biomarkers 26 (circulating molecules, physiological traits, and other pathologies) and targets linked with 27 coronary artery disease. [12, 13] The potency and replicability of associations, coupled with the 28 inherent mechanisms delineated by foundational medicine, have led researchers to causally link 29 certain novel biomarkers and targets with MI [14, 15]. Subsequent interventions aiming to prevent 30 these identified "risk factors" have been initiated. However, differences often emerge between 31 these findings and those observed in epidemiological settings [16]. The ambiguity surrounding the 32 causal roles of numerous biomarkers during disease progression together with the steep costs of 33 drug development programs reveals the necessity to distinguish between "causality" and mere 34 "association" [17].

35

36 Mendelian Randomization (MR) as a Research Tool

37 MR offers a robust statistical apparatus, furnishing a unique approach to investigating causal 38 relationships between exposures and outcomes [18, 19]. By using genetic variations as 39 instrumental variables to estimate the causal effects of plasma proteins on MI, we can obtain more

1 precise causal estimates than conventional observational studies [14–17]. Notably, MR studies on

- 2 plasma proteins and MI predominantly feature a few proteins grounded in extant knowledge,
- 3 sidelining a variety of other proteins potentially correlated with MI risk.
- 4

5 Research Aims and Methodology

6 This study endeavors to leverage the MR framework to holistically analyze potential causal 7 relationships between thousands of plasma proteins and MI risk, streamlining the identification of 8 novel MI drug targets. Our methodology incorporates the selection of independent genetic loci, 9 significantly correlated with protein levels and proximate to protein-encoding gene locations, as 10 instrumental variables, substantially mitigating the possibility for violating instrumental variable 11 assumptions. We further fortify our results through a series of sensitivity analyses. We anticipated 12 that this investigation will shed comprehensive insights, serving as a cornerstone for MI drug 13 target research and development.

14

METHODS 15

Data Source And Disclosure Statement 16

The database for genetic variations associated with plasma proteins has been sourced from 17 18 deCODE genetics/Amgen, Inc., Reykjavik, Iceland. The database for genetic variations associated 19 with myocardial infarction (MI) has been obtained from two major repositories: the UK BioBank 20 and the CARDIoGRAM+C4D Consortium. Both of these databases are publicly accessible, in 21 accordance with data sharing policies. 22

Discovery analysis 23

Mendelian randomization 24

25 Figure 1 illustrates the working principle of Mendelian randomization. Firstly, we define certain 26 mathematical symbols as depicted in the figure. We denote the independent instrumental variables 27 (IVs) as gi. Here, X represents exposure, Y stands for the outcome, and U signifies the 28 confounders. The aggregate effects of gi on X and Y are represented as β_{Xi} and β_{Yi} , respectively. 29



- 2 Fig. 1 The working principle of Mendelian randomization
- 3

1

4 To avoid the potential for biased inference from horizontal pleiotropy (where IVs affect Y not just 5 through X), Mendelian randomization requires three core instrumental variable (IV) assumptions 6 [20]:

7 (A1) Relevance assumption: The genetic variants used as instruments are associated with the 8 exposure. Mathematically, the IV is correlated with exposure X; that is, $\gamma_i \neq 0$.

9 (A2) Independence assumption: The genetic variation and the outcome of interest share no

10 common causes (i.e., no confounders). Mathematically speaking, the IV is uncorrelated with the outcome Y given the exposure X; that is, $\alpha_i = 0$. 11

12 (A3) Exclusion restriction assumption: There are no independent pathways between the genetic

13 variation and the outcome apart from through the exposure. Mathematically, the IV is uncorrelated

14 with unmeasured confounders U: namely, $\varphi_i = 0$.

15 Given the above assumptions, we have equations (1) and (2):

$$16 \quad \beta_{Xi} = \gamma_i + \beta_{XU} \cdot \varphi_i \tag{1}$$

 $\beta_{Yi} = \theta \cdot \beta_{Xi} + \alpha_i + \beta_{YU} \cdot \varphi_i$ 17

18 =
$$\theta \cdot \gamma_i + \beta_{XU} \cdot \varphi_i + \alpha_i + \beta_{YU} \cdot \varphi_i$$

19
$$= \theta \cdot \beta_{Xi} + r_i \quad (\text{where } r_i = \alpha_i + \beta_{YU} \cdot \varphi_i)$$
 (2)

20 Under the circumstance of assumption (A2) and (A3), $\alpha_i = 0$ $\varphi_i = 0$. Then, we collect causal effect 21 $\theta = \beta_{Yi} / \beta_{Xi}$, which is called wald ratio.

22

IV Selection and Validation 23

24 Genetic variations utilized as IVs need to adhere to the three assumptions previously stated. The 25 first of these assumptions postulates a correlation between genetic variations and the exposure, 26 (various types of plasma proteins). To substantiate this assumption, we drew upon the findings of a 27 genome-wide association study (GWAS) conducted by Ferkingstad, E. et al[21]. This study delved

perpetuity. All rights reserved. No reuse allowed without permission.

into the associations of 27.2 million genetic variants with 4,907 aptamers, quantifying 4,719
plasma proteins in a sample of 35,559 Icelanders (courtesy of the Icelandic Cancer Project and deCODE genetics, Reykjav'ık, Iceland). Subsequent to this, we applied rigorous filters to this pool of pQTLs, eliminating: 1. Non-biallelic single nucleotide polymorphism (SNPs); 2. SNPs with minor allele frequency (MAF) < 0.01; 3. Variants located either on the sex chromosomes or within the human major histocompatibility complex (MHC) region.
To satisfy Assumptions 2 and 3, we employed more stringent criteria in selecting pQTLs: 1. Only pQTLs located within 200kb upstream of the transcription start site or 200kb downstream of the

pOTLs located within 200kb upstream of the transcription start site or 200kb downstream of the 9 10 termination site of their corresponding protein-coding genes were included and labeled as 11 cis-pQTLs; 2. For these cis-pQTLs, we counted the number of proteins associated with each 12 pQTL, as well as those linked to this pQTL in linkage disequilibrium (LD R2 > 0.5). We then 13 excluded pQTLs that had associations with more than five proteins. It's worth noting that our 14 criteria for selecting cis-pQTLs are stricter than those in many standard studies. Our primary aim 15 is to ensure the instrumental variables (IVs or pQTLs) we choose influence the outcome (MI) 16 solely through their corresponding proteins, thus minimizing the impact of horizontal pleiotropy 17 on our MR estimates.

18

19 Finally, to mitigate the impact of correlation between IVs on the MR estimates, we clumped the 20 above-selected IVs (pQTLs). In alignment with Albert's research, we controlled LD R2 between 21 IVs below 0.4[22]. This threshold is backed by evidence suggesting that the issue of unstable 22 coefficient estimation due to collinearity begins to manifest when the LD R2 between independent 23 variables exceeds 0.36[23]. Subsequently, we assessed the strength of each IV for every protein. 24 Proteins with insufficient IV strength (with an F – statistic < 10) were excluded, ensuring that the 25 IVs we employed effectively represented genetic proxies of protein levels. Through these rigorous 26 quality control measures, we ensured our chosen IVs for MR analysis faithfully adhered to the 27 foundational three assumptions of Mendelian Randomization.

28

29 Statistical analysis

30 For our primary MR analysis, we utilized the IVs shortlisted from the aforemen- tioned 31 procedures. The data for our outcome variable, MI, was extracted from a GWAS encompassing 32 approximately 831,000 individuals of European ancestry, an amalgamation of several contributory 33 cohorts. Within this, the UK Biobank provided data on 17,505 MI cases and 454,212 controls. It 34 pinpointed 1.966 single-nucleotide polymorphisms (SNPs) spread across 31 loci, all exhibiting 35 associations with MI and surpassing the genome-wide significance threshold ($P=5*10^{-8}$). In 36 contrast, the CARDIoGRAM+C4D Consortium contributed information on 61,000 MI cases, 37 578,000 controls, and a sweeping range of 8,126,035 SNPs. Of these, 4,419 variants, dispersed 38 over 80 loci, were deemed significant.

39

In scenarios where only one IV corresponded to a protein, we employed the wald ratio method to
estimate the causal effect. However, for proteins linked to two or more IVs, we use MR-Egger
[24], the inverse variance weighted method (IVW) [25], weighted mode method [26], simple

43 mode method [24] and weighted median method [27] for our MR estimation. To ensure precision,

1 we use Bonferroni correction to adjust the MR results. Associations reflecting a P -value < 0.05/

2 (the number of proteins assessed in MR) were classified as significant. We use R package

3 "TwoSampleMR" (https://github.com/MRCIEU/TwoSampleMR) to execute MR analysis.

4

Sensitivity analysis 5

6 Horizontal Pleiotropy Test

7 Horizontal pleiotropy arises when a genetic variation affects the outcome via path- ways other 8 than the primary exposure, which can introduce biases into previously calculated MR estimates. 9 To address this, we employ Egger regression [28] to assess the presence of horizontal pleiotropy. 10 Theoretically, in the absence of horizontal pleiotropy, IVs impact the outcome solely through the 11 exposure. Within this regression model, the slope quantifies the effect of exposure on the outcome, 12 while the intercept serves as an indicator for pleiotropy. A significant deviation of the intercept 13 from zero signals the existence of horizontal pleiotropy.

14

15 **Heterogeneity Test**

16 A fundamental assumption of Mendelian randomization (MR) is that genetic variations correlate 17 with the exposure but are independent of any confounding factors that could bias the causal 18 association between the exposure and the outcome. However, the genetic variations utilized as 19 instrumental variables (IVs) might sometimes violate this assumption. This can occur if they are 20 related to other factors influencing the outcome or different genetic variations impact the exposure 21 through diverse pathways. In MR analysis, the heterogeneity test serves as an essential tool to 22 assess if the genetic variations used as IVs align with the MR assumptions.

23 A widely employed method to conduct this heterogeneity test is Cochran's Q test[29]. The specific 24 steps are:

25 (1) For each genetic variation, define
$$\hat{\beta}_i^{IV} = \frac{\hat{\beta}_{Yi}}{\hat{\beta}_{Xi}}$$
 with an approximate standard error given by

 $SE(\hat{\beta}_i^{IV}) = \frac{SE(\hat{\beta}_{Yi})}{\hat{\beta}_{Yi}}$, where $\hat{\beta}_{Xi}$ and $\hat{\beta}_{Yi}$ represent the effects of the IV on the exposure and 26 27 outcome, respectively.

(2) Compute the statistic $Q = \sum_{i} \omega_i (\hat{\beta}_i^{IV} - \hat{\beta}^{IV})^2$, where $\omega_i = SE(\hat{\beta}_i^{IV})^{-2}$ is the inverse 28 variance weight and $\hat{\beta}^{IV} = \frac{\sum_i \omega_i \hat{\beta}_i^{IV}}{\sum_i \omega_i}$ is the inverse variance-weighted estimate based on all 29 30 genetic variations (fixed effects).

- 31 (3) Under the null hypothesis, the statistic Q follows a chi-squared distribution $\chi^2(I-1)$. If this 32 is significant, it indicates heterogeneity among the genetic variations, suggesting potential 33 violations of MR assumptions.
- 34

35 **Reverse causation**

36 Although the motivation of Mendelian randomization is to avoid bias from unmeasured

1 confounding and reverse causation, the method may invalidate causal conclusions in several 2 circumstances [30]: Genetic association with the risk factor is not primary, Feedback mechanism 3 and Cross-generational effects. To enhance the robustness of our Mendelian randomization, we 4 implemented MR-Steiger method [31] to undertake a directionality test. Additionally, we conduct 5 a reverse Mendelian Randomization to verify whether there exists causation from MI to plasma 6 proteins, which utilize MI as an exposure and plasma proteins as outcome. 7

8 Colocalization

9 Proximal variants often inherit together and therefore are usually correlated, which is termed as 10 linkage disequilibrium law in genetics. Two traits might be causally influenced by distinct variants 11 that happen to be correlated, providing a pathway between genetic variation and an outcome not 12 mediated by the exposure, which could violate the exclusion restriction assumption of Mendelian 13 randomization. We employ colocalization analysis to determine whether a specific genetic locus's 14 variant is associated with both a plasma protein (a particular exposure) and MI (a health outcome). 15 The central premise of colocalization analysis is to determine whether a particular variation at a 16 genetic locus is associated with both an exposure and a health outcome. We use R package "coloc" 17 (https://github.com/chr1swallace/coloc) to execute colocalization analysis.

Potential Drug target 18

19 To investigate the current state of drug development focused on these identified proteins, we 20 consulted three specialized databases: the DrugBank Database, the PharmGKB Database, and the 21 Therapeutic Target Database (TTD), each with its own unique features. The DrugBank Database 22 [32] offers comprehensive data on FDA- approved as well as experimental drugs, including details 23 on drug targets, mechanisms of action, and drug interactions. PharmGKB[33], provides 24 international drug labeling information over various countries, including the United States, 25 Canada, Europe, Switzerland, and Japan. The TTD Database [34] offers valuable literature-based 26 information on known therapeutic protein and nucleic acid targets, targeted disease conditions, 27 pathways information and the respective drugs or ligands for each target.

28

Ethics statement 29

30 Patients or the public were not involved in the design, conduct, reporting or dissemination plans of

- 31 our research.
- 32

Results 1

IV selection and validation 2

3 Ferkingstad, E. et al's research delved into the associations of 27.2 million genetic variants with 4 4,907 aptamers, quantifying 4,719 plasma proteins in a sample of 35,559 Icelanders (courtesy of 5 the Icelandic Cancer Project and deCODE genetics, Reykjavik, Iceland). From this extensive 6 dataset, we earmarked 4,631 proteins as potential exposures and identified 28,191 pQTLs associated with these proteins (P-value $< 1.8 \times 10^{-9}$, (0.05/27.2 million)) as candidate IVs for our 7 Mendelian Randomization (MR) analysis. After excluding IVs to satisfy the assumption of MR 8 9 analysis, we select 3674 IVs associated with 1502 plasma proteins.

10

11 Then subsequent to clumping at an LD R2 threshold of 0.4 to obtain IVs for each exposure 12 (plasma protein) and calculated the IV strength for each protein to ensure that these IVs were a 13 good genetic proxy for the corresponding plasma protein level (F-statistics were all greater than 14 20), we validate 3156 IVs associated with 1487 plasma proteins. Take IV-outcome dataset into 15 consideration, we harmonize the IV-exposure data and IV-outcome data, we have 2965 IVs 16 associated with 1422 plasma proteins. See Supplementary Material(IV selection and 17 validation.xlsx) for more information.

18

Proteome-wide MR analysis identified 15 plasma proteins 19

significantly associated with MI risk 20

21 After primary MR analysis, 15 of these 1,422 proteins showed a significant genetically predicted 22 causal association with MI risk (P -value < 3.510-5 (0.05/1,422))(Table 1). Considering that 23 protein levels were rank-inverse normal transformed in the protein GWAS, for MR results, we 24 paid more attention to the direction of the estimates than the magnitude of the estimates. Among 25 these 15 significant proteins(Table 1), genetically predicted plasma levels of 26 Plasminogen(Plasmin), Hepatocyte growth factor-like protein(MSP), Apolipoprotein B(Apo B), 27 Transgelin-2(TAGLN2), Low-density lipoprotein receptor-related protein 4(LRP4), Complement 28 C1s subcomponent(C1s), Angiostatin, Apolipoprotein C-III(Apo C-III), Proprotein convertase 29 subtilisin/kexin type 9(PCSK9), Angiopoietin-related protein 4(ANGL4) were associated with 30 higher MI risk, while the genetically predicted plasma levels of Fibronectin Fragment 4(FN1.4), 31 Apolipoprotein B(Apo B), Interleukin-6 receptor subunit alpha(IL-6 sRa), Switch-associated 32 protein 70(SWAP70), Fibronectin, Fibronectin Fragment 3(FN1.3) were associated with lower MI 33 risk.

34

Sensitivity Analysis demonstrated the robustness of 7 1

candidate potential drug targets 2

3 Horizontal pleiotropy test

4 First, we performed a horizontal pleiotropy test to judge whether several SNPs associated with one 5 protein has horizontal pleiotropy. According to Table 2, all the selected proteins passed the 6 horizontal pleiotropy test with egger intercept apart from zero, indicating there exists no horizontal 7 pleiotropy in the selected SNPs, fitting the assumption of Mendelian randomization.

8

9 Heterogeneity test

10 Secondly, we conducted a heterogeneity test sensitivity analysis. Our results revealed that proteins 11 Plasmin and Angiostatin had Cochran's O P-values lower than 0.05. This suggests significant 12 heterogeneity among these proteins, violating the assumption of Mendelian randomization. This 13 warrants special consideration in subsequent analyses.

14

Reverse Causality Analysis 15

16 Thirdly, a reverse causality analysis was conducted, indicating that proteins MSP, Apo B, 17 Angiostatin demonstrated reverse causality effects on MI. This could mean that myocardial 18 infarction (MI) caused the expression of these plasma proteins, which, as originally thought, are 19 not our founding potential targets for MI.

20

21 **Colocalization Analysis**

22 Lastly, in the colocalization analysis, at a threshold of 0.8, several proteins were found to share the 23 with MI(Table 3), including Apo В (rs12713844; rs563290). same variants 24 Transgelin-2(rs2789422), LRP4(rs2306029; rs4752946), C1s(rs12146727), Apo C-III (rs964184), 25 PCSK9(rs11591147; rs472495; rs505151; rs58255540) and ANGL4(rs116843064). When the 26 threshold was lowered to 0.7, additional variants in SWAP70 (rs10743116; rs12271923; 27 rs2645017; rs415895) were also deemed to share the same variants with MI.

28

29 Through this comprehensive set of analyses, we identified 7 candidate potential drug targets 30 related to myocardial infarction (MI) more accurately, including SWP70, TAGLN2, LRP4, C1s, 31 Apo C-III, PCSK9 and ANGL4, while also shedding light on possible false positives and false 32 negatives. These findings will help deepen our understanding of the molecular mechanisms 33 underlying MI and could have a positive impact on future drug development targeting this 34 condition.

35

Drugability assessment of potential drug targets 36

37 We searched DrugBank, PharmGKB, and TTD databases to fully evaluate the Drugability of our 38 selected potential drug targets. According to the 3 databases, potential drug targets were classified 39 into four categories: Successful Target (drugs targeting this protein have been successfully

1 approved), Clinical trial Target (drugs targeting this protein are undergoing clinical trials), 2 Literature-reported Target (this protein has been reported in the literature as a potential drug 3 target), Not currently listed as druggable (no research using this protein as a drug target has been 4 retrieved).(Table 4) In general, C1s is a successful target for Hereditary angioedema and Cold type 5 autoimmune haemolytic anemia; Apo C-III, PCSK9 are Clinical trial Targets ;TAGLN2 and 6 ANGL4, are Literature-reported Target ; LRP4 and SWP70 is Not currently listed as druggable. 7

Discussion 8

9 In the present study, we used proteome-wide GWAS data to conduct a Mendelian randomization 10 analysis. After a series of stringent quality control measures to validate IVs, we obtained IVs that 11 satisfied the three core assumptions of MR. Using these IVs, we identified 15 candidate plasma 12 proteins (Plasminogen(Plasmin), Hepatocyte growth factor-like protein(MSP), Apolipoprotein 13 B(Apo B), Transgelin-2(TAGLN2), Low-density lipoprotein receptor-related protein 4(LRP4), 14 Complement C1s subcomponent(C1s), Angiostatin, Apolipoprotein C-III(Apo C-III), Proprotein 15 convertase subtilisin/kexin type 9(PCSK9), Angiopoietin-related protein 4(ANGL4), Fibronectin 16 Fragment 4(FN1.4), Apolipoprotein B(Apo B), Interleukin-6 receptor subunit alpha(IL-6 sRa), 17 Switch-associated protein 70(SWAP70), Fibronectin, Fibronectin Fragment 3(FN1.3)) casually 18 associated with MI. A full range of sensitivity analyses confirmed the robustness in the primary 19 analysis, selecting candidate plasma proteins including PCSK9,LRP4,APO 7 20 C-III,ANGL4,SWP70,TAGLN2 and C1s. Finally, by searching multiple drug databases, we have a 21 full understanding of the current status of drug development targeting these proteins, and suggest 22 the possibility of multiple uses for approved drugs and new MI therapeutic targets.

23

24 Protein targets associated with decrease of LDL-C

25 Elevated cholesterol levels, especially high levels of low-density lipoprotein cholesterol (LDL-C), 26 increase the risk of atherosclerosis (also known as coronary heart disease). In this condition, 27 cholesterol and other lipids accumulate on the walls of the blood vessels, forming "plaques". 28 These plaques can lead to arterial narrowing and hardening, restricting blood flow. When the 29 coronary arteries (the main vessels supplying blood to the heart) are severely narrowed or blocked, 30 the rupture of an unstable plaque followed by subsequent blood clot formation can trigger a 31 myocardial infarction (heart attack). High LDL-C levels increase the risk of the formation and 32 rupture of such unstable plaques. [35]

33

34 PCSK9

35 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is A successful target for Familial 36 hypercholesterolemia and Chronic obstructive pulmonary disease. The Low- Density Lipoprotein 37 Receptor (LDLR) modulates blood cholesterol levels by binding to and clearing circulating LDL. 38 It acts on low-density lipoprotein receptors (LDLR) and targets them for degradation, thus 39 reducing the liver's ability to remove LDL- cholesterol from the bloodstream, playing a crucial 40 role in cholesterol metabolism. Inhibitors of PCSK9 are used to treat high levels of 41 LDL-cholesterol. [36]

perpetuity. All rights reserved. No reuse allowed without permission.

1

2 Several research reveals that the use of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) 3 inhibitors (monoclonal antibodies) can reduce LDL-C levels. Fourier et al.'s experiment [37] 4 revealed that treatment with Evolocumab significantly reduced the risk of the composite outcome 5 of cardiovascular death, MI, stroke, unstable angina, or coronary revascularization by 19%. The 6 ODYSSEY outcome trial [38, 39] also showed similar results. Alirocumab significantly reduced 7 the risk of the primary endpoint by 15% (HR 0.85, 95% CI 0.78–0.93, P = 0.003). In a recent 8 meta-analysis of 67 randomized controlled trials (RCTs) [40] including 259,429 participants, 9 PCSK9 inhibitors plus statin significantly reduced the risk of non-fatal MI (RR 0.82,95% CI 0.72-10 0.93, p=0.003) or stroke (RR 0.74,95% CI 0.65–0.85, p<<0.001). This provides strong support for 11 future drug research aiming at improving myocardial infarction outcomes by targeting this 12 mechanism.

- 13
- 14 *LRP4*

15 LRP4 is not currently listed as druggable in the drug database, however its super family LRP5 and 16 LRP6 are clinical trial Targets for solid tumour/cancer through Wnt/β-catenin signaling pathway 17 [41, 42], where LRP4 also holds a pivotal position. Wnt/ β -catenin signaling, a complex and highly 18 conserved cell signaling system, plays a crucial role in the patterning, morphogenesis and growth 19 of a variety of tissues and organs during development and in homeostasis in the adult, While 20 Aberrant Wnt signaling activity is causally linked to degenerative diseases and cancers [43, 44], 21 MI included. Three main phases, inflammation, angiogenesis and fibrosis [45, 46], widely 22 recognized following MI, may exacerbate Wnt/β-catenin signaling and interfere with the balanced 23 cardiac remodeling, thus these events could aggravate tissue damage and cause heart failure.

24

Recent research has found new therapeutic strategy to treat MI, using inhibitors of the canonical
Wnt/β-catenin signaling pathway [47, 48],like anti-cancer drugs in patients after MI to prevent
heart failure. Early using of these drugs in the first days after myocardial infarction can could
inhibit Wnt signaling pathway, limit the loss of cardiomyocytes and fibrosis, thus promote
myocardial regeneration, prevent adverse cardiac remodeling and improve LV function. [49] Dkk1
is one representative of the inhibitors which can enhance ischemic injury by promoting the
internalization and elimination of basal LRP4/5.[50]

32

33 Protein targets associated with balance of TG

34 Apo C-III

Apolipoprotein C-III (ApoCIII) is a clinical trial target, while its messenger RNA (APOC3 mRNA)
has become a successful target for Hypertriglyceridemia and Hyperlipoproteinemia. This protein
has its unique proatherogenic effect on metabolism dysfunction of TGs and other various lipid
molecules, as well as its influence on acceleration of pro-inflammatory effects between monocytes
and endothelial cells, causing the high risk of MI. [51] In a follow-up randomized controlled trial,
Mendivil et al. [52] highlighted that the coronary heart disease risk posed by LDL is primarily due
to the presence of apoC-III within the LDL.

42

In a retrospective case-control study, Gerber et al[53] investigated 90 consecutive patients with
CHD and compared them with 209 hospital-based controls, finding an significant odds ratio in a

1 cardiovascular event(OR=1.82,95% CI 1.18-2.79, p=0.003),in a non-HDL apoC-III (OR=2.44,95%

2 CI 1.58-3.78, pi0.001), HDL apoC-III(OR=0.64.95% CI 0.42-0.96, p=0.09), with each SD

3 increase in total serum apoC-III.

4 ANGL4

5 ANGL4 is a Literature-reported Target. Lipoprotein lipase (LPL) hydrolyzes fatty acids from 6 triglyceride-rich lipoproteins and regulates their distribution to peripheral tissues. ANGL4 7 mediates the inactivation of the lipoprotein lipase LPL [54, 55], thus playing a significant role in 8 regulating serum triglyceride clearance and lipid metabolism. This has been confirmed by several 9 human genome-wide association studies [56–59]. Numerous genetic studies indicate that elevated 10 plasma triglycerides are associated with increased risk factors for cardiovascular disease [54, 55, 11 60]. Given ANGL4's role in lipid regulation, ANGL4 is widely considered a potential drug target 12 for cardiovascular diseases. It has been reported that plasma ANGL4 levels can predict future 13 cardiovascular events, suggesting that ANGL4 might serve as a biomarker for coronary artery 14 disease, including myocardial infarction [61], and an effective drug target.

15

16 Protein targets associated with decrease of LDL-C

17 SWP70

18 SWAP 70 is not currently listed as a therapeutic target. Preliminary evidence from animal studies 19 have shown that SWAP 70 may inhibit the development of non-alcoholic fatty liver disease 20 (NAFLD) by suppressing lipid accumulation, inflammatory responses, and fibrosis. An ELISA 21 study [35, 36] suggests that the SWAP-70 antibody may serve as a biomarker for the recurrence 22 and prognosis of multiple sclerosis (MS). In the context of cardiovascular diseases, a gene 23 knockout experiment [37] has shown that SWAP70 could inhibit the progression of cardiac 24 hypertrophy, possibly through TAK1-dependent suppression of the mitogen-activated protein 25 kinase signaling pathway. Lysosomes may also be involved in regulating the expression levels of 26 SWAP70. Though its potential role in the prevention and treatment of myocardial infarction 27 requires further investigation, these findings indicate a promising avenue for future research, 28 especially in the realm of therapeutic applications.

29

30 Protein targets with other mechanism

31 TAGLN2

32 TAGLN2 is a literature reported target. TAGLN2 is an actin-binding protein expressed in smooth 33 muscle cells, related to the formation of the cytoskeletal structure, and plays a role in cell 34 migration and tissue repair. Since smooth muscle cells and vascular repair have certain roles in the 35 development of cardiovascular diseases, including myocardial infarction, it is theoretically 36 possible that TAGLN2 may have an indirect association with cardiovascular diseases. Most 37 studies on TAGLN2 focus on its relationship with non-cardiovascular diseases such as cancer, 38 inflammation, and autoimmune diseases. Further research is needed to determine whether it can 39 serve as a reliable biomarker and potential drug target for myocardial infarction.

40

41 C1s

42 C1s is a successful target. Complement system and C1s plays a critical role in maintaining 43 homeostasis, which is associated with dysfunction and many disorders. The C1 complex, 44 composed of C1q, C1r, and C1s (C1qr2s2), is the initiator of the classical complement activation

perpetuity. All rights reserved. No reuse allowed without permission.

1 pathway. At molecular level, C1r activates C1s so that it can, in turn, activate C2 and C4. C1s B

2 chain is a serine protease that combines with C1q and C1r to form C1, which the first component

3 of the classical pathway of the complement system. As C1s is activated under various pathological

4 conditions and associated with the development of inflammation, autoimmunity and cancer, it has
5 become an outstanding biomarker or target for diagnosis and treatment to large quantities of

6 disease.

7

8 C1s has been a successful target for Hereditary angioedema and Cold type autoimmune 9 haemolytic anemia, but remains literature-reported for MI. Complement system and C1s plays a 10 critical role in maintaining homeostasis, which is associated with dysfunction and many disorders, 11 including cardiovascular artery diseases like MI. [62] C1s is a member of the SCUBE1 family 12 [63], which is a platelet granule protein that is exposed on the surface of platelets upon activation. 13 Activated platelets are key factors in the development of arteriosclerosis. [64] Lin's research [65] 14 suggests that SCUBE may be a crucial platelet-endothelial adhesion molecule in the 15 pathophysiology of cardiovascular disease development. As C1s is activated under various 16 pathological conditions and associated with the development of inflammation, autoimmunity and 17 cancer, it has become an outstanding biomarker or target for diagnosis and treatment to large 18 quantities of disease. More researches can be conducted to use C1s as a target for MI.

19

20 Our study has a lot of advantages.

Comprehensive Data Analysis: By using an expansive dataset from the Icelandic Cancer
 Project and deCODE genetics, we were able to capture associations between a broad array of
 genetic variants and plasma proteins.

24 2. Robustness through MR Analysis: Mendelian Randomization allows for the identification of
25 causal relationships, minimizing the impact of confounding factors typically encountered in
26 observational studies.

27 3. Rigorous Sensitivity Analyses: Through heterogeneity tests, reverse causality analyses, and
28 colocalization analyses, we added layers of validation to our findings, making our conclusions
29 more robust.

4. Practical Implications: Our study does not merely identify genetic associations; it has
tangible implications for the identification of potential drug targets, speeding up the typically long
drug development process.

33

34 However, our study still has some limitations.

Potential Population Bias: Our study heavily relies on data from Icelandic individuals. While
 it provides a comprehensive dataset, the findings might not be generalizable to populations with
 different genetic backgrounds.

38 2. Incomplete Drugability Assessment: Though we explored drugability using prominent
39 databases, emerging research or less-established potential drug targets might have been
40 overlooked.

3. Complexity of MI Pathogenesis: MI is a multifactorial condition, and while our study sheds
light on certain causal factors, there might be other significant variables or interactions not
captured in our analysis.

4. Limitations of MR: Despite the strengths of MR, it's based on several key assumptions, such

as the relevance and exclusion criteria. If any of these are violated, it might introduce biases.

3 Conclusion

Our study represents a significant stride in understanding the causal relationships between plasma proteins and MI risk. By harnessing the power of Mendelian Randomization and extensive genetic datasets, we've pinpointed promising drug targets for MI, offering a beacon of hope for streamlining future therapeutic interventions. However, as with all research, our findings have certain limitations. Further research in diverse populations and incorporating more extensive drugability datasets will be essential to validate and expand upon our conclusions.

10

11 Supplementary information

12 IV selection and validation.xlsx is result of IV selection and validation.

13

14 Sources of Funding

15 This work was supported by Peking University.

16

17 **Conflict of Interest Disclosures**

18 None.

References

[1] Pollard, T.J.: The acute myocardial infarction. Primary Care: Clinics in Office Practice 27(3), 631-649 (2000)

[2] Salari, N., Morddarvanjoghi, F., Abdolmaleki, A., Rasoulpoor, S., Khaleghi, A.A., Hezarkhani, L.A., Shohaimi, S., Mohammadi, M.: The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovascular Disorders 23(1), 206 (2023)

[3] Dundar, Y., Hill, R., Dickson, R., Walley, T.: Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. Qim 96(2), 103-113 (2003)

[4] Imming, P., Sinning, C., Meyer, A.: Drugs, their targets and the nature and number of drug targets. Nature reviews Drug discovery 5(10), 821-834 (2006)

[5] Gashaw, I., Ellinghaus, P., Sommer, A., Asadullah, K.: What makes a good drug target? Drug discovery today 16(23-24), 1037–1043 (2011)

[6] Lam, M.P., Ping, P., Murphy, E.: Proteomics research in cardiovascular medicine and biomarker discovery. Journal of the American College of Cardiology 68(25), 2819–2830 (2016)

[7] Hartiala, J.A., Han, Y., Jia, Q., Hilser, J.R., Huang, P., Gukasyan, J., Schwartz- man, W.S., Cai, Z., Biswas, S., Tregouet, D.-A., et al.: Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. European heart journal 42(9), 919–933 (2021)

[8] Gao, H., Li, L., Rao, S., Shen, G., Xi, Q., Chen, S., Zhang, Z., Wang, K., Ellis, S.G., Chen, Q., et al.: Genome-wide linkage scan identifies two novel genetic loci for coronary artery disease: in genequest families. PLoS One 9(12), 113935 (2014)

[9] Wang, Z., He, Z., Xuan, Q., Zhang, Y., Xu, J., Lin, J., Li, H., Chen, W., Jiang, T.: Analysis of the potential ferroptosis mechanism and multitemporal expression change of central ferroptosis-related genes in cardiac ischemia-reperfusion injury. Frontiers in Physiology 13, 934901 (2022)

[10] Grimes, D.A., Schulz, K.F.: Bias and causal associations in observational research. The lancet 359(9302), 248-252 (2002)

[11] Hern'an, M.A.: Methods of public health research-strengthening causal inference from observational data. New England Journal of Medicine 385(15), 1345-1348 (2021)

[12] Zakynthinos, E., Pappa, N.: Inflammatory biomarkers in coronary artery disease. Journal of cardiology 53(3), 317-333 (2009)

[13] Sun, X., Jia, Z.: A brief review of biomarkers for preventing and treating cardiovascular diseases. Journal of cardiovascular disease research 3(4), 251 (2012)

[14] Bisoendial, R.J., Kastelein, J.J., Levels, J.H., Zwaginga, J.J., Bogaard, B., Reitsma, P.H., Meijers, J.C., Hartman, D., Levi, M., Stroes, E.S.: Activation of inflammation and coagulation after infusion of c-reactive protein in humans. Circulation Research 96(7), 714-716 (2005)

[15] Tall, A.: An overview of reverse cholesterol transport. European heart journal 19, 31-5 (1998)

[16] Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D.D., et al.: Effects of torcetrapib in patients at high risk for coronary events. New England journal of medicine 357(21), 2109–2122 (2007)

[17] Kannel, W.B., CASTELLI, W.P., GORDON, T.: Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the framingham study. Annals of internal Medicine 90(1), 85–91 (1979)

[18] Xue, H., Shen, X., Pan, W.: Constrained maximum likelihood-based mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. The American Journal of Human Genetics 108(7), 1251–1269 (2021)

[19] Thanassoulis, G., O'Donnell, C.J.: Mendelian randomization: nature's randomized trial in the post-genome era. Jama 301(22), 2386-2388 (2009)

[20] Bowden, J., Holmes, M.V.: Meta-analysis and mendelian randomization: A review. Research synthesis methods 10(4), 486-496 (2019)

[21] Ferkingstad, E., Sulem, P., Atlason, B.A., Sveinbjornsson, G., Magnusson, M.I., Styrmisdottir, E.L., Gunnarsdottir, K., Helgason, A., Oddsson, A., Halldorsson, B.V., et al.: Large-scale integration of the plasma proteome with genetics and disease. Nature genetics 53(12), 1712–1721 (2021)

[22] Henry, A., Gordillo-Mara n'on, M., Finan, C., Schmidt, A.F., Ferreira, J.P., Karra, R.,

Sundstr"om, J., Lind, L., "Arnl"ov, J., Zannad, F., et al.: Therapeutic targets for heart failure

identified using proteomics and mendelian randomization. Circulation 145(16), 1205–1217 (2022)

[23] Burgess, S., Zuber, V., Valdes-Marquez, E., Sun, B.B., Hopewell, J.C.: Mendelian randomization with fine-mapped genetic data: choosing from large numbers of correlated instrumental variables. Genetic epidemiology 41(8), 714-725 (2017)

[24] Hartwig, F.P., Davey Smith, G., Bowden, J.: Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. International journal of epidemiology 46(6), 1985–1998 (2017)

[25] Burgess, S., Bowden, J.: Integrating summarized data from multiple genetic variants in mendelian randomization: bias and coverage properties of inverse-variance weighted methods. arXiv preprint arXiv:1512.04486 (2015)

[26] Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al.: The mr-base platform supports systematic causal inference across the human phenome. elife 7, 34408 (2018)

[27] Bowden, J., Davey Smith, G., Haycock, P.C., Burgess, S.: Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genetic epidemiology 40(4), 304–314 (2016)

[28]Bowden, J., Davey Smith, G., Burgess, S.: Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. International journal of epidemiology 44(2), 512–525 (2015)

[29] Burgess, S., Bowden, J., Fall, T., Ingelsson, E., Thompson, S.G.: Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. Epidemiology (Cambridge, Mass.) 28(1), 30 (2017)

[30] Burgess, S., Swanson, S.A., Labrecque, J.A.: Are mendelian randomization investigations immune from bias due to reverse causation? European Journal of Epidemiology 36, 253–257 (2021)

[31] Hemani, G., Tilling, K., Davey Smith, G.: Orienting the causal relationship between imprecisely measured traits using gwas summary data. PLoS genetics 13(11), 1007081 (2017)

[32] Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al.: Drugbank 5.0: a major update to the drugbank database for 2018. Nucleic acids research 46(D1), 1074–1082 (2018)

[33]Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C.F., Whaley, R., Klein, T.E.: An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics 110(3), 563–572 (2021)

[34] Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., Chen, Y.: Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research 50(D1), 1398–1407 (2022)

[35] Xu, S., Bendeck, M., Gotlieb, A.: Vascular pathobiology: Atherosclerosis and large vessel disease. In: Cardiovascular Pathology, pp. 85–124. Elsevier (2016)

[36] Guo, S., Xia, X.-d., Gu, H.-m., Zhang, D.-w.: Proprotein convertase subtilisin/kexin-type 9 and lipid metabolism. Lipid Transfer in Lipoprotein Metabolism and Cardiovascular Disease, 137-156 (2020)

[37] Gencer, B., Mach, F., Murphy, S.A., De Ferrari, G.M., Huber, K., Lewis, B.S., Ferreira, J., Kurtz, C.E., Wang, H., Honarpour, N., et al.: Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a pre- specified secondary analysis from the fourier trial. JAMA cardiology 5(8), 952-957 (2020)

[38] Schwartz, G.G., Bessac, L., Berdan, L.G., Bhatt, D.L., Bittner, V., Diaz, R., Goodman, S.G., Hanotin, C., Harrington, R.A., Jukema, J.W., et al.: Effect of alirocumab, a monoclonal antibody to pcsk9, on long-term cardiovascular out- comes following acute coronary syndromes: rationale and design of the odyssey outcomes trial. American heart journal 168(5), 682-689 (2014)

[39] Steg, P.G., Schwartz, G., Szarek, M., et al.: The odyssey outcomes trial: topline results alirocumab in patients after acute coronary syndrome. Presented by Dr. Philippe Steg at the American College of Cardiology Annual Scientific Session (ACC 2018), Orlando, FL 10 (2018)

[40] Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkin- stian, A., Reid, C., Wongcharoen, W., Chaiyakunapruk, N.: Effects of non-statin lipid-modifying agents on cardiovascular morbidity and mortality among statin- treated patients: a systematic review and network meta-analysis. Frontiers in pharmacology 10, 547 (2019)

[41] Li, Y., Bu, G.: Lrp5/6 in wnt signaling and tumorigenesis (2005)

[42] Joiner, D.M., Ke, J., Zhong, Z., Xu, H.E., Williams, B.O.: Lrp5 and lrp6 in development and disease. Trends in Endocrinology & Metabolism 24(1), 31-39 (2013)

[43] Clevers, H., Nusse, R.: Wnt/β-catenin signaling and disease. Cell 149(6), 1192–1205 (2012)

[44] Komiya, Y., Habas, R.: Wnt signal transduction pathways. Organogenesis 4(2), 68–75 (2008)

[45] Fang, L., Moore, X.-L., Dart, A.M., Wang, L.-M.: Systemic inflammatory response following acute myocardial infarction. Journal of geriatric cardiology: JGC 12(3), 305 (2015)

[46] Cleutjens, J.P., Blankesteijn, W.M., Daemen, M.J., Smits, J.F.: The infarcted myocardium: simply dead tissue, or a lively target for the apeutic interventions. Cardiovascular research 44(2), 232-241 (1999)

[47] Stangl, V., Baumann, G., Stangl, K., Felix, S.B.: Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovascular research 53(1), 12-30 (2002)

[48] James, T.N.: The chronotropic action of atp and related compounds studied by direct perfusion of the sinus node. Journal of Pharmacology and Experimental Therapeutics 149(2), 233–247 (1965)

[49] Procopio, M.C., Lauro, R., Nasso, C., Carerj, S., Squadrito, F., Bitto, A., Di Bella, G., Micari, A., Irrera, N., Costa, F.: Role of adenosine and purinergic receptors in myocardial infarction: focus on different signal transduction pathways. Biomedicines 9(2), 204 (2021)

[50] Zheng, J.-S., Boluyt, M.O., O'Neill, L., Crow, M.T., Lakatta, E.G.: Extracellular atp induces immediate-early gene expression but not cellular hypertrophy in neonatal cardiac myocytes. Circulation research 74(6), 1034–1041 (1994)

[51] Jin, J.-L., Guo, Y.-L., Li, J.-J.: Apoprotein c-iii: A review of its clinical implications. Clinica Chimica Acta 460, 50–54 (2016)

[52] Mendivil, C.O., Rimm, E.B., Furtado, J., Chiuve, S.E., Sacks, F.M.: Low-density lipoproteins containing apolipoprotein c-iii and the risk of coronary heart disease. Circulation 124(19), 2065–2072 (2011)

[53] Gerber, Y., Goldbourt, U., Segev, S., Harats, D.: Indices related to apo cii and ciii serum concentrations and coronary heart disease: a case–control study. Preventive medicine 37(1), 18–22 (2003)

[54] Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S.M., Khaw, K.-T., Gudnason, V.: Triglycerides and the risk of coronary heart disease:
10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation 115(4), 450–458 (2007)

[55] Jeppesen, J.ø., Hein, H.O., Suadicani, P., Gyntelberg, F.: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the copenhagen male study. Circulation 97(11), 1029–1036 (1998)

[56] Dewey, F.E., Gusarova, V., O'Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C.V., Habegger, L., Buckler, D., Lai, K.-M.V., et al.: Inactivating variants in angpt14 and risk of coronary artery disease. New England Journal of Medicine 374(12), 1123–1133 (2016)

[57] Genetics, M.I., Investigators, C.E.C.: Coding variation in angptl4, lpl, and svep1 and the risk of coronary disease. New England Journal of Medicine 374(12), 1134–1144 (2016)

[58] Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., Hjartarson, E., Sigurdsson, A., Magnusdottir, A., Jonasdottir, A., Kristjansson, H., Sulem, P., Oddsson, A., et al.: Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature genetics 48(6), 634–639 (2016)

[59] Romeo, S., Pennacchio, L.A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H.H., Cohen, J.C.: Population-based resequencing of angptl4 uncovers variations that reduce triglycerides and increase hdl. Nature genetics 39(4), 513–516 (2007)

[60] Reiner, Z^{*}.: Hypertriglyceridaemia and risk of coronary artery disease. Nature Reviews Cardiology 14(7), 401–411 (2017)

[61] Muendlein, A., Saely, C.H., Leiherer, A., Fraunberger, P., Kinz, E., Rein, P., Vonbank, A., Zanolin, D., Malin, C., Drexel, H.: Angiopoietin-like protein 4 significantly predicts future cardiovascular events in coronary patients. Atherosclerosis 237(2), 632–638 (2014)

[62] Ye, J., Yang, P., Yang, Y., Xia, S.: Complement c1s as a diagnostic marker and therapeutic target: Progress and prospective. Frontiers in Immunology 13, 1015128 (2022)

[63] Tu, C.-F., Su, Y.-H., Huang, Y.-N., Tsai, M.-T., Li, L.-T., Chen, Y.-L., Cheng, C.-J., Dai, D.-F., Yang, R.-B.: Localization and characterization of a novel secreted protein scube1 in human platelets. Cardiovascular research 71(3), 486–495 (2006)

[64] Huo, Y., Schober, A., Forlow, S.B., Smith, D.F., Hyman, M.C., Jung, S., Littman, D.R., Weber, C., Ley, K.: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein e. Nature medicine 9(1), 61–67 (2003)

[65] Lin, Y.-C., Sahoo, B.K., Gau, S.-S., Yang, R.-B.: The biology of scube. Journal of biomedical science 30(1), 1–45 (2023)

| exposure | method | nsnp | snp | b | se | b_CI | OR | OR_CI | p-value |
|-------------|---------------------------|------|------------------------|--------|-------|------------------|-------|----------------|-----------|
| TAGLN2 | Wald ratio | 1 | rs2789422 | 0.394 | 0.087 | (0.224, 0.564) | 1.483 | (1.251, 1.757) | 5.46E-06* |
| SWP70 | Weighted median | 3 | rs12271923,rs2645017, | -0.082 | 0.018 | (-0.116, -0.047) | 0.922 | (0.89, 0.954) | 3.72E-06* |
| | Inverse variance weighted | | rs415895 | -0.083 | 0.017 | (-0.117, -0.05) | 0.92 | (0.889, 0.952) | 1.39E-06* |
| | Simple mode | | | -0.086 | 0.029 | (-0.142, -0.03) | 0.917 | (0.867, 0.97) | 0.0947 |
| | Weighted mode | | | -0.081 | 0.018 | (-0.117, -0.045) | 0.922 | (0.89, 0.956) | 0.0474 |
| | MR Egger | | | -0.07 | 0.035 | (-0.138, -0.002) | 0.932 | (0.871, 0.998) | 0.291 |
| IL-6 sRa | Weighted median | 4 | rs12083537,rs12126142, | -0.036 | 0.007 | (-0.05, -0.021) | 0.965 | (0.951, 0.979) | 9.39E-07* |
| | Inverse variance weighted | | rs140604580,rs61812626 | -0.035 | 0.009 | (-0.054, -0.017) | 0.965 | (0.948, 0.983) | 1.68E-03 |
| | Simple mode | | | -0.034 | 0.01 | (-0.054, -0.014) | 0.967 | (0.948, 0.986) | 0.0452 |
| | Weighted mode | | | -0.035 | 0.008 | (-0.051, -0.019) | 0.965 | (0.95, 0.981) | 0.0222 |
| | MR Egger | | | -0.039 | 0.021 | (-0.079, 0.002) | 0.962 | (0.924, 1.002) | 0.202 |
| LRP4 | Inverse variance weighted | 2 | rs2306029,rs4752946 | 0.075 | 0.017 | (0.041, 0.109) | 1.078 | (1.042, 1.115) | 1.31E-05* |
| Apo B | Wald ratio | 1 | rs563290 | 0.516 | 0.109 | (0.303, 0.729) | 1.675 | (1.354, 2.073) | 2.08E-06* |
| FN1.3 | Wald ratio | 1 | rs1250258 | -0.266 | 0.053 | (-0.369, -0.163) | 0.767 | (0.692, 0.85) | 4.25E-07* |
| FN1.4 | Wald ratio | 1 | rs1250259 | -0.271 | 0.052 | (-0.374, -0.169) | 0.762 | (0.688, 0.845) | 2.21E-07* |
| Angiostatin | Weighted median | 4 | rs10945684,rs11751347, | 0.167 | 0.037 | (0.095, 0.239) | 1.182 | (1.1, 1.27) | 5.28E-06* |
| | Inverse variance weighted | | rs1652492,rs4252185 | -0.017 | 0.322 | (-0.648, 0.614) | 0.984 | (0.523, 1.848) | 0.959 |

 Table 1
 15 Plasma Proteins Identified Causally Associated with MI Risk

| | Simple mode | | | 0.235 | 0.039 | (0.158, 0.312) | 1.265 | (1.171, 1.366) | 9.42E-03 |
|-------------|---------------------------|---|-----------------------|--------|-------|------------------|-------|----------------|-----------|
| | Weighted mode | | | 0.2 | 0.04 | (0.123, 0.278) | 1.222 | (1.13, 1.321) | 0.015 |
| | MR Egger | | | -0.089 | 0.644 | (-1.351, 1.173) | 0.915 | (0.259, 3.233) | 0.903 |
| ANGL4 | Wald ratio | 1 | rs116843064 | 0.449 | 0.095 | (0.262, 0.636) | 1.566 | (1.3, 1.888) | 2.48E-06* |
| Fibronectin | Wald ratio | 1 | rs1250258 | -0.236 | 0.047 | (-0.328, -0.145) | 0.79 | (0.721, 0.865) | 4.25E-07* |
| Plasminogen | Weighted median | 4 | rs11751347,rs4252159, | 0.222 | 0.037 | (0.149, 0.296) | 1.249 | (1.161, 1.344) | 2.48E-09* |
| | Inverse variance weighted | | rs4252185,rs6938647 | -0.038 | 0.341 | (-0.707, 0.63) | 0.963 | (0.493, 1.878) | 0.911 |
| | Simple mode | | | 0.088 | 0.052 | (-0.015, 0.19) | 1.092 | (0.985, 1.209) | 0.192 |
| | Weighted mode | | | 0.231 | 0.036 | (0.161, 0.3) | 1.259 | (1.174, 1.35) | 7.48E-03 |
| | MR Egger | | | 0.514 | 0.665 | (-0.789, 1.817) | 1.672 | (0.454, 6.152) | 0.52 |
| MSP | Wald ratio | 1 | rs1131095 | 0.032 | 0.007 | (0.019, 0.046) | 1.033 | (1.019, 1.047) | 1.42E-06* |
| PCSK9 | Weighted median | 4 | rs11591147,rs472495, | 0.257 | 0.04 | (0.179, 0.335) | 1.293 | (1.196, 1.398) | 1.03E-10* |
| | Inverse variance weighted | | rs505151,rs58255540 | 0.268 | 0.041 | (0.188, 0.348) | 1.308 | (1.207, 1.417) | 5.78E-11* |
| | Simple mode | | | 0.182 | 0.086 | (0.014, 0.35) | 1.2 | (1.014, 1.42) | 0.124 |
| | Weighted mode | | | 0.33 | 0.041 | (0.249, 0.41) | 1.39 | (1.283, 1.507) | 3.99E-03 |
| | MR Egger | | | 0.358 | 0.048 | (0.263, 0.453) | 1.43 | (1.301, 1.572) | 0.0178 |
| Apo C-III | Wald ratio | 1 | rs964184 | 0.262 | 0.052 | (0.161, 0.364) | 1.3 | (1.175, 1.439) | 4.01E-07* |
| C1s | Wald ratio | 1 | rs12146727 | 0.06 | 0.014 | (0.032, 0.088) | 1.062 | (1.033, 1.092) | 2.28E-05* |

*: significant P-value. For a particular plasma protein, although p-values for some methods is not extremely significant, the OR range is similar to those methods with significant P-values.

Abbreviation of plasma proteins(exposure): TAGLN2:Transgelin-2; SWP70:Switch-associated protein 70; IL-6 sRa:Interleukin-6 receptor subunit alpha;

LRP4:Low-density lipoprotein receptor-related protein 4; Apo B:Apolipoprotein B; FN1.3:Fibronectin Fragment 3; FN1.4:Fibronectin Fragment 4; ANGL4:Angiopoietin-related protein 4; Plasmin: Plasminogen; MSP: Hepatocyte growth factor-like protein; PCSK9:Proprotein convertase subtilisin/kexin type 9; Apo C-III: Apolipoprotein C-III; C1s:Complement C1s subcomponent

| Table 2 Sensitivity test of 15 candidate proteins | |
|---|--|
| | |

| | | | Horizontal pleiotropy test | | | Heterogeneity test | | | D |
|-------------|------|------------------------|----------------------------|--------|---------|--------------------|------|-----------|--------------|
| exposure | nsnp | snp | Egger intercept | se | p-value | Q | Q_df | Q_p-value | Keverse |
| TAGLN2 | 1 | rs2789422 | | | | | | | |
| SWP70 | 3 | rs12271923,rs2645017, | -0.0043 | 0.01 | 0.7395 | 0.3623 | 2 | 0.8343 | |
| | | rs415895 | | | | | | | |
| IL-6 sRa | 4 | rs12083537,rs12126142, | 0.0028 | 0.0145 | 0.8655 | 5.0337 | 3 | 0.1693 | |
| | | rs140604580,rs61812626 | | | | | | | |
| LRP4 | 2 | rs2306029,rs4752946 | | | | 0.0046 | 1 | 0.9461 | |
| Apo B | 1 | rs563290 | | | | | | | 1 |
| FN1.3 | 1 | rs1250258 | | | | | | | |
| FN1.4 | 1 | rs1250259 | | | | | | | |
| Angiostatin | 4 | rs10945684,rs11751347, | 0.0153 | 0.108 | 0.9006 | 334.103 | 3 | 4.13E-72 | \checkmark |
| | | rs1652492,rs4252185 | | | | | | | |
| ANGL4 | 1 | rs116843064 | | | | | | | |
| Fibronectin | 1 | rs1250258 | | | | | | | |
| Plasminogen | 4 | rs11751347,rs4252159, | -0.1266 | 0.1304 | 0.4341 | 332.7267 | 3 | 8.20E-72 | |
| | | rs4252185,rs6938647 | | | | | | | |
| MSP | 1 | rs1131095 | | | | | | | 1 |

| PCSK9 | 4 | rs11591147,rs472495, | -0.0257 | 0.0109 | 0.1427 | 5.624 | 3 | 0.1314 |
|-----------|---|----------------------|---------|--------|--------|-------|---|--------|
| | | rs505151,rs58255540 | | | | | | |
| Apo C-III | 1 | rs964184 | | | | | | |
| C1s | 1 | rs12146727 | | | | | | |

* Cochran's Q P-values<0.05, indicating significant heterogeneity

Proteins associated with single snp share no pleiotropy. All the selected proteins passed the horizontal pleiotropy test. Plasmin and Angiostatin didn't pass the heterogeneity test. MSP, Apo B, Angiostatin has a reverse causality.

Table 3Colocalization Analysis

| variant | protein | outcome | coloc-prob |
|---|-------------|---------|------------|
| rs10743116 | SWP70 | MI | 71.60% |
| rs12271923 | | | 71.66% |
| rs2645017 | | | 72.02% |
| rs415895 | | | 71.73% |
| rs12083537; rs12126142;rs140604580;rs61812626 | IL-6 sRa | MI | 0.94% |
| rs2306029 | LRP4 | MI | 94.89% |
| rs4752946 | | | 94.90% |
| rs12713844; rs563290 | Apo B | MI | 92.00% |
| rs1250258 | FN1.3 | MI | 1.24% |
| rs1250259 | FN1.4 | MI | 0.60% |
| rs139078629 | | | 1.46% |
| rs10945684; rs11751347; rs1652492; rs4252185 | Angiostatin | MI | 0.00% |
| rs116843064 | ANGL4 | MI | 99.81% |
| rs1250258 | Fibronectin | MI | 1.08% |
| rs11751347; rs4252159; rs4252185; rs6938647 | Plasminogen | MI | 0.00% |
| rs1131095; rs142690032; rs3197999 | MSP | MI | 9.75% |
| rs11591147; rs472495; rs505151; rs58255540 | PCSK9 | MI | 100.00% |
| rs964184 | Apo C-III | MI | 99.80% |
| rs12146727 | C1s | MI | 96.86% |
| rs2789422 | TAGLN2 | MI | 99.11% |



Fig. 2 Results of selected proteins with single snp

| Plasma Proteins | OR (95% CI) | Method | | Method |
|-----------------|-------------------|-----------------|---------|------------------|
| SWP70 | 0.93 (0.87, 1.00) | MR Egger | | IVW |
| | 0.92 (0.89, 0.95) | Weighted median | - | MR Egger |
| | 0.92 (0.89, 0.95) | IVW | | Simple mode |
| | 0.92 (0.87, 0.97) | Simple mode | | Weighted median |
| | 0.92 (0.89, 0.96) | Weighted mode | | - Weighted mode |
| IL-6 sRa | 0.96 (0.92, 1.00) | MR Egger | · · · - | |
| | 0.96 (0.95, 0.98) | Weighted median | • | |
| | 0.97 (0.95, 0.98) | IVW | • | |
| | 0.97 (0.95, 0.99) | Simple mode | • | |
| | 0.97 (0.95, 0.98) | Weighted mode | • | |
| LRP4 | 1.08 (1.04, 1.11) | IVW | | - |
| Angiostatin | 0.92 (0.26, 3.23) | MR Egger | | |
| | 1.18 (1.10, 1.27) | Weighted median | | |
| | 0.98 (0.52, 1.85) | IVW | | |
| | 1.26 (1.17, 1.37) | Simple mode | | |
| | 1.22 (1.13, 1.32) | Weighted mode | | |
| Plasminogen | 1.67 (0.45, 6.15) | MR Egger | | |
| | 1.25 (1.16, 1.34) | Weighted median | | |
| | 0.96 (0.49, 1.88) | IVW | | |
| | 1.09 (0.99, 1.21) | Simple mode | | |
| | 1.26 (1.17, 1.35) | Weighted mode | | - - |
| PCSK9 | 1.43 (1.30, 1.57) | MR Egger | | _ |
| | 1.29 (1.20, 1.40) | Weighted median | | |
| | 1.31 (1.21, 1.42) | IVW | | |
| | 1.20 (1.01, 1.42) | Simple mode | | |
| | 1.39 (1.28, 1.51) | Weighted mode | | |
| | | | 0.5 1 | 1.5 2 |
| | | | | Odds Ratio |

Fig. 3 Results of selected proteins with several snps

 Table 4 Drugability assessment of potential drug targets

| Protein | Target Info | Target Name | Target type | Disease | Drugs |
|--------------|----------------|--|-------------------------------|---|---------------|
| TAGLN2 | T93147 | Transgelin-2 (TAGLN2) | Literature-reported Target | not Available | not Available |
| SWP70 | | | | | |
| LRP4 | | | | | |
| Apo B | T07533 | Apolipoprotein B-100 (APOB) | Clinical trial Target | High blood cholesterol level | SPC4955 |
| | T09507 | APOB messenger RNA (APOB mRNA) | Successful Target | Familial hypercholesterolemia; Hypercholesterolaemia | Mipomersen |
| ANGL4 | T98635 | Angiopoietin-related protein 4 (ANGPTL4) | Literature-reported Target | Not Available | Not Available |
| PCSK9 | T62206 | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Successful Target | Familial hypercholesterolemia; Chronic obstructive pulmonary disease;COPD | REGN-727 |
| | T86652 | PCSK9 messenger RNA (PCSK9 mRNA) | Clinical trial Target | Cardiovascular disease; Metabolic disorder | MPSK3169A |
| Apo C-III | T86115 | ApoC-III messenger RNA (APOC3 mRNA) | Successful Target | Successful Target | Volanesorsen |
| | T31518 | Apolipoprotein C-III (ApoCIII) | Clinical trial Target | Not Available | Not Available |
| C1s | T76024 | Complement C1s component (C1S) | Successful Target | Hereditary angioedema; Cold type autoimmune haemolytic anemia | Cinryze |